haloperidol has been researched along with carteolol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Kikuchi, T; Morita, S; Nakai, M; Tottori, K; Uwahodo, Y | 1 |
| Kudo, S; Odomi, M | 1 |
| Aoki, S; Hisazumi, H; Isawa, S; Kudo, S; Kumagai, Y; Miura, S; Murasaki, M; Uchiumi, M; Yoshioka, M | 1 |
7 other study(ies) available for haloperidol and carteolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.
Topics: Adrenergic beta-Antagonists; Animals; Antipsychotic Agents; Carteolol; Catalepsy; Haloperidol; Locomotion; Male; Rats; Rats, Wistar | 1997 |
Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antiparkinson Agents; Biotransformation; Biperiden; Carteolol; Cell Line, Transformed; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Haloperidol; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes; Mixed Function Oxygenases; Oxidation-Reduction; Quinidine; Sparteine; Troleandomycin | 1998 |
Pharmacokinetic and pharmacodynamic interactions among haloperidol, carteolol hydrochloride and biperiden hydrochloride.
Topics: Adrenergic beta-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Biperiden; Carteolol; Cholinergic Antagonists; Drug Interactions; Drug Therapy, Combination; Haloperidol; Humans; Male; Pupil; Sleep Stages | 1999 |